Core Insights - Atossa Therapeutics has received Orphan Drug Designation from the FDA for (Z)-endoxifen to treat Duchenne muscular dystrophy (DMD), which is a significant milestone for the company in its development efforts for this serious disease [1][2] Group 1: Company Overview - Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology and other areas with high unmet medical needs [7] - The company's lead product candidate, (Z)-endoxifen, is being evaluated for its potential applications in oncology and rare diseases [5][7] - Atossa has a growing global intellectual property portfolio supporting the (Z)-endoxifen program, including multiple recently issued U.S. patents and numerous pending applications worldwide [6] Group 2: Product Information - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/SERD) with demonstrated activity across multiple mechanisms of interest, showing a favorable safety profile distinct from tamoxifen [5] - The drug is not yet approved for any indication, and the company plans to continue engaging with the FDA as it advances its development efforts [2][5] Group 3: Disease Context - Duchenne Muscular Dystrophy (DMD) is a rare, progressive, X-linked neuromuscular disorder caused by mutations in the dystrophin gene, leading to severe symptoms and a substantial unmet medical need for effective treatments [4]

Financial Position - As of December 31, 2025, Atossa Therapeutics, Inc. estimated cash and cash equivalents of approximately $40 million[6] - The financial results for the year ended December 31, 2025, are still subject to finalization and should not be solely relied upon[7] Development Strategy - The company is focusing on the development and regulatory strategy for (Z)-Endoxifen, with potential market opportunities being explored[10] Risks and Compliance - Forward-looking statements indicate potential risks and uncertainties related to clinical development timelines and regulatory approvals[11] - The company aims to regain and maintain compliance with Nasdaq listing requirements as part of its strategic objectives[11]

Core Insights - Atossa Therapeutics has received a "Study May Proceed" letter from the FDA for its clinical study of (Z)-endoxifen in metastatic breast cancer, marking a significant regulatory milestone for the company [1][2] Group 1: Product Development - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with demonstrated activity across multiple mechanisms, currently under evaluation for oncology and rare diseases [3] - The proprietary oral formulation of (Z)-endoxifen has shown a favorable safety profile and distinct pharmacology compared to tamoxifen, including ER-targeted effects and PKC inhibition [3] - The (Z)-endoxifen program is supported by a growing global intellectual property portfolio, including multiple recently issued U.S. patents and numerous pending applications worldwide [4] Group 2: Company Overview - Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines in oncology and other areas of significant unmet medical need [5] - The company's lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings [5]

Core Insights - Atossa Therapeutics has been awarded the Research and Development Award in the Precision Endocrine Therapy category at the 2025 Clinical Trials Arena Excellence Awards for its work on (Z)-endoxifen [1][3] Group 1: Product Development - (Z)-endoxifen is a selective estrogen receptor modulator/degrader (SERM/D) designed to provide consistent systemic exposure independent of CYP2D6 metabolism, with applications in metastatic, neoadjuvant, adjuvant breast cancer, and Duchenne Muscular Dystrophy (DMD) [2][4] - The therapy has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition [4] Group 2: Company Strategy - Atossa emphasizes disciplined capital allocation, focusing on programs that can enable future regulatory submissions and potential commercialization [6] - The company is supported by a growing global intellectual property portfolio, including multiple recently issued U.S. patents and numerous pending applications worldwide [5] Group 3: Leadership and Innovation - The award reflects the company's commitment to precision endocrine therapy and its integrated approach to developing (Z)-endoxifen for patients with high unmet medical needs [3] - The Clinical Trials Arena Excellence Awards recognize companies demonstrating scientific rigor, innovation, and leadership in clinical research and drug development [3]

Core Insights - Atossa Therapeutics presented four clinical trial updates on (Z)-endoxifen at the San Antonio Breast Cancer Symposium, highlighting its potential in breast cancer treatment and risk reduction [1][2] Clinical Trial Updates - The company emphasized the therapeutic value of (Z)-endoxifen across the breast care continuum, with ongoing enrollment in the Phase 2 EVANGELINE study for neoadjuvant ER+/HER2- breast cancer [2] - Initial results from the RECAST trial suggest that short-term endocrine therapy combined with MRI response assessment may help identify low-risk DCIS patients who can avoid surgery [3][7] - Low-dose (Z)-endoxifen demonstrated excellent tolerability and biological activity, with significant reductions in Ki-67 (–72% median), MRI tumor volume, and ctDNA clearance in 70% of initially ctDNA-positive patients [5][8] - The EVANGELINE trial is the first to evaluate (Z)-endoxifen with ovarian function suppression as a neoadjuvant therapy for premenopausal ER+/HER2- breast cancer, showing strong early biological activity with 86% of patients achieving a Week 4 Ki-67 of 10% [10][15] Mechanistic Insights - (Z)-endoxifen maintains potent ER antagonist activity against key ESR1 mutations, stabilizing inactive receptor conformations and demonstrating strong suppression of ER signaling [6][14] - Transcriptomic analyses indicate that (Z)-endoxifen reverses multiple mutant ESR1-associated oncogenic pathways while restoring beneficial programs, highlighting its therapeutic potential for ER+/ESR1 mutant breast cancer [14]

Core Viewpoint - Atossa Therapeutics is advancing its regulatory strategy for (Z)-endoxifen, focusing on expedited pathways for metastatic, neoadjuvant, and risk-reduction settings in breast cancer treatment [1][2]. Regulatory Strategy - The company completed a Type C meeting with the FDA on November 17, 2025, which provided feedback on potential expedited regulatory pathways and development options for (Z)-endoxifen [1][2]. - The meeting clarified routes to accelerate clinical development and regulatory review, allowing Atossa to pursue a faster development strategy across multiple breast cancer indications [2][3]. Clinical Development - Atossa has submitted an Investigational New Drug (IND) application for its metastatic breast cancer program and anticipates additional IND submissions in 2026 to explore combination strategies [4]. - The clinical program has involved nearly 800 participants across multiple trials, with a focus on creating value-creating milestones [5]. Product Profile - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) that can inhibit and potentially degrade estrogen receptors, showing activity in tumors resistant to other therapies [5]. - The company is developing a proprietary oral formulation of (Z)-endoxifen that bypasses stomach acid, enhancing bioavailability and therapeutic integrity [6]. Intellectual Property - Atossa's (Z)-endoxifen program is supported by a growing global intellectual property portfolio, including four recently issued U.S. patents and numerous pending applications worldwide [7]. Clinical Trials and Indications - The company is preparing a dose-ranging study for metastatic breast cancer and continues enrollment in the Phase 2 EVANGELINE trial for neoadjuvant ER+/HER2- breast cancer [9]. - Development efforts also include a low-dose strategy targeting mammographic breast density and overall breast cancer risk [9].

Core Insights - Eviden, a product brand of Atos Group, has announced the rankings of its 58 supercomputers in the TOP500 and Green500 lists, highlighting its leadership in advanced computing and energy efficiency [1][3]. Group 1: Supercomputer Rankings - JUPITER, through its Booster partition, is ranked as the 4th most powerful supercomputer globally and the 1st in Europe, marking a historic achievement as the first European system to surpass the ExaFlop barrier, performing one billion billion calculations per second [2][5]. - JUPITER is recognized as the most energy-efficient exascale-class supercomputer, achieving 63 GigaFlops per watt, which demonstrates superior performance-per-watt compared to its competitors [6][9]. Group 2: Green500 Leadership - Eviden has maintained its lead in the Green500 rankings for the fourth consecutive edition, with KAIROS, ROMEO, and Levante GPU extension occupying the top three positions, achieving 73, 70, and 69 GFlops per watt respectively [3][8]. - The Green500 ranking emphasizes the importance of energy efficiency in high-performance computing, with higher GFlops per watt indicating lower energy consumption and costs [8]. Group 3: Innovation and Sustainability - The achievements of Eviden underscore its commitment to innovation, performance, and sustainability, facilitating the adoption of AI and large-scale simulations for various scientific and technological advancements [4][9]. - JUPITER's development involved sustainable design practices and aims to set global efficiency standards, forming the core of the JUPITER AI Factory, which will provide secure access to AI models for research and industry [7][9]. Group 4: Company Overview - Eviden operates in 36 countries with approximately €1 billion in revenue, focusing on advanced computing, cybersecurity products, mission-critical systems, and vision AI [10]. - The company employs over 4,500 professionals and holds more than 2,100 patents, offering a robust portfolio of innovative and eco-efficient solutions in AI, computing, security, data, and applications [11]. Group 5: Atos Group Context - Atos Group, with around 67,000 employees and annual revenue of approximately €10 billion, is a global leader in digital transformation, emphasizing a secure and decarbonized future [12]. - The Group operates under two brands, Atos for services and Eviden for products, and is committed to providing tailored AI-powered solutions across various industries [12][13].

Core Insights - Atossa Therapeutics is advancing its investigational therapy (Z)-endoxifen for Duchenne Muscular Dystrophy (DMD) and associated pathologies, supported by new scientific publications and presentations [1][2][5] Mechanism and Efficacy - The published hypothesis article outlines how (Z)-endoxifen's pharmacology may address multiple disease drivers in DMD, including inflammation, fibrosis, and mitochondrial dysfunction [2][3] - (Z)-endoxifen modulates estrogen receptors and inhibits PKC, potentially slowing disease progression when used alongside standard care [3][6] - The therapy may provide more consistent therapeutic exposure compared to tamoxifen by avoiding CYP2D6 metabolic variability [3] Research Developments - A second manuscript is under review, focusing on (Z)-endoxifen's role in modulating utrophin expression, which could offer a mutation-agnostic therapeutic approach for DMD [4] - Atossa plans to leverage the published framework for preclinical validation and clinical study design, assessing safety and pharmacodynamics relevant to muscle and cardiac performance [9] Target Population - The upcoming presentation will address symptomatic female carriers of DMD, a group that may experience significant health issues, with 2.5–19% showing skeletal muscle symptoms and 7.3–16.7% developing dilated cardiomyopathy [5][10] Strategic Outlook - The company emphasizes the need for a multi-pathway approach to DMD treatment, positioning (Z)-endoxifen as a potentially scalable and accessible option alongside genetic therapies [15] - Management highlights the importance of rigorous testing and regulatory engagement to accelerate development for patients [7][8]

Drug Development - The company is developing (Z)-endoxifen for both the prevention and treatment of breast cancer, with a focus on metastatic breast cancer and mammographic breast density reduction [84][89]. - In a Phase 2 study, the 1 mg dose of (Z)-endoxifen reduced mammographic breast density (MBD) by 17.3% (p<0.01), while the 2 mg dose achieved a reduction of 23.5% (p<0.01), compared to a minimal change of 0.27% in the placebo group [96]. - The company has completed four Phase 1 clinical studies and two Phase 2 clinical studies for (Z)-endoxifen, demonstrating significant progress in clinical development [92]. - The FDA has provided positive feedback regarding the proposed global Phase 2 dose optimization trial for (Z)-endoxifen in patients with ER+/HER2- metastatic breast cancer, paving the way for a potential IND submission targeted for Q4 2025 [89]. - The company is pursuing a Type C meeting with the FDA to discuss an accelerated regulatory strategy for low-dose (Z)-endoxifen for breast cancer risk reduction, with a meeting scheduled for November 17, 2025 [87]. - The company has received authorization from the FDA for its IND application for oral (Z)-endoxifen, with a Phase 2 study assessing its use as neoadjuvant therapy in premenopausal women with primary ER+, HER2- breast cancer [101]. - Approximately 240 patients are expected to be treated in the ongoing Phase 2 DCIS study, which investigates (Z)-endoxifen as a neoadjuvant treatment for ductal carcinoma in situ [99]. - The company has patent protection for (Z)-endoxifen through at least November 17, 2038, ensuring intellectual property rights for its proprietary drug [85]. Financial Performance - Total operating expenses increased to $9.3 million for the three months and $25.7 million for the nine months ended September 30, 2025, compared to $6.4 million and $20.5 million for the same periods in 2024, representing increases of 45% and 25% respectively [114]. - Research and Development (R&D) expenses totaled $5.4 million for the three months and $15.0 million for the nine months ended September 30, 2025, up 57% and 40% from $3.4 million and $10.7 million in 2024 [115]. - Clinical and non-clinical trial expenses rose by $1.8 million and $3.3 million for the three and nine months ended September 30, 2025, primarily due to increased spending on (Z)-endoxifen trials [121]. - Interest income decreased to $0.6 million and $1.9 million for the three and nine months ended September 30, 2025, down from $1.0 million and $3.2 million in 2024, reflecting lower average balances in the money market account [117]. - Net cash used in operating activities was $19.2 million for the nine months ended September 30, 2025, compared to $14.0 million in 2024, indicating an increase of $5.2 million [123]. - As of September 30, 2025, the company had $51.8 million in cash and cash equivalents, with working capital of $47.5 million, sufficient to fund projected operating requirements for at least the next 12 months [123]. - The company reported a net loss of $23.8 million for the nine months ended September 30, 2025 [123]. Clinical Trials and Studies - The Phase 2 EVANGELINE study was amended to reduce the patient total from 214 to 40-65, focusing on objective, short-interval endpoints [104]. - In the ongoing I-SPY 2 EOP trial, 95% of participants completed at least 75% of planned dosing, with median Ki-67 falling from 10.5% at baseline to 5% by Week 3 [106]. Operational Strategy - The company aims to shorten clinical development timelines and reduce costs through an accelerated path to filing a New Drug Application (NDA) with the FDA [82]. - The company is exploring the potential of artificial intelligence (AI) in its product candidates, which may enhance development efficiency and outcomes [88]. - The company entered into an operating lease for additional office space at $3 thousand per month for 13 months starting November 1, 2025 [110]. - The company expects ongoing operating losses as it continues to develop therapeutic programs, impacting future funding requirements [126]. - An increase of $2.7 million in cash used for clinical and non-clinical trials, including drug development costs [128]. - Estimated non-cancellable commitments as of September 30, 2025, amount to $7.8 million, to be paid over the term of clinical trials [132]. Funding and Market Conditions - The company may face challenges in raising additional funding due to uncertain market conditions, including inflation and high interest rates [127]. - The company received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share [131]. - A decrease of $1.3 million in cash provided by interest income due to lower amounts invested in the money market account [128]. - The company may need to modify or delay development programs if adequate funds are not available [127]. - The company has no off-balance sheet arrangements or relationships with unconsolidated entities [133]. - The company may elect to raise additional funds even before they are needed if capital raising conditions are favorable [130]. - The company is subject to potential adverse effects on stockholder rights if additional funds are raised through equity offerings [127].

Financial Performance - Atossa Therapeutics reported total operating expenses of $9.3 million for Q3 2025, an increase of $2.9 million compared to Q3 2024[6]. - Operating expenses for the three months ended September 30, 2025, were $9,251,000, compared to $6,385,000 for the same period in 2024, representing a 45.5% increase[24]. - The net loss for the three months ended September 30, 2025, was $8,692,000, compared to a net loss of $7,230,000 for the same period in 2024[24]. - The company reported a net loss per share of $0.07 for the three months ended September 30, 2025, compared to $0.06 for the same period in 2024[24]. - Total current assets decreased from $74,457,000 as of December 31, 2024, to $55,678,000 as of September 30, 2025[22]. - Total liabilities increased from $4,967,000 as of December 31, 2024, to $8,225,000 as of September 30, 2025[22]. Research and Development - Research and Development (R&D) expenses for Q3 2025 were $4.3 million, a 73% increase from $2.5 million in Q3 2024, driven by higher spending on (Z)-endoxifen trials[8]. - Clinical and non-clinical trial expenses increased by $1.8 million for Q3 2025 compared to Q3 2024, primarily due to (Z)-endoxifen development costs[12]. - Atossa is developing a proprietary enteric oral formulation of (Z)-endoxifen, which enhances bioavailability and therapeutic integrity by bypassing stomach acid[15]. - Clinical studies involving over 700 subjects have shown that (Z)-endoxifen is well tolerated, with no maximum tolerated dose identified at doses up to 360 mg/day[15]. - The (Z)-endoxifen program is currently being evaluated in three Phase 2 studies, including one for DCIS and two for ER+/HER2- breast cancer[16]. Regulatory and Strategic Initiatives - Atossa plans to submit an Investigational New Drug (IND) application for (Z)-endoxifen in Q4 2025, aligning with FDA feedback under the Project Optimus initiative[7]. - The company has streamlined its Phase 2 EVANGELINE study to prioritize NDA-enabling activities for (Z)-endoxifen, aiming for accelerated readouts and reduced costs[3]. - The company received preliminary comments from the FDA regarding the regulatory path for (Z)-endoxifen and expects to discuss a development plan in a Type C meeting on November 17, 2025[3]. - Atossa is pursuing an accelerated regulatory path for (Z)-endoxifen, with updates on milestones expected by the end of 2025[16]. Management and Intellectual Property - Atossa appointed Janet R. Rea as Senior Vice President of R&D and Mark Daniel as Chief Financial Officer to enhance its commercialization strategy[4]. - Atossa's Israeli patent for (Z)-endoxifen was granted on July 2, 2025, reinforcing its intellectual property strategy[7]. - Atossa's intellectual property portfolio includes three recently issued U.S. patents and numerous pending applications worldwide[16].